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Background: IXIARO (JESPECT® in Australia, IC51), Inter-
cell’s recently approved Vero cellderived, inactivated
Japanese Encephalitis vaccine, has been proven immuno-
genic and safe in a 0/ 28 Day primary immunization schedule
in adults. Neutralizing antibody titers decline with time and
booster doses are likely needed to obtain a longer last-
ing immune response. Objectives: To assess the effect of
a booster dose on neutralizing antibody titers for up to 12
months after the booster.
Methods: In this open-label phase III trial, 198 sub-
jects, who had received their primary immunization in a
preceding randomized trial, were boosted with IXIARO 15
months after the primary immunization and followed up for
12 months. Neutralizing antibody titers were assessed by
plaque-reduction neutralization test, PRNT on the day of
boosting and 1, 6 and 12 months later. A PRNT50≥ 1:10 was
the cut-off for seroconversion. Systemic and local tolerabil-
ity were solicited with diaries for a 7 days period following
the booster.
Results: Prior to the booster, 69.2% (137/198) of subjects
had PRNT50 titers of ≥1:10. The seroconversion rate (SCR)
was 100% (198/198) one month after the booster. Both at 6
months and 12 months after the booster, the SCR remained
high at 98.5% (194/197 and 191/194 subjects, respectively).
GMTs were 22.5 before the booster and 900, 487 and 361 at
1, 6 and 12 months after the booster. During 7 days after the
booster, 30.8% of subjects reported solicited local reactions,
and 23.2% reported solicited systemic adverse events.
Conclusion: An IXIARO booster 15 months after primary
immunization induced higher neutralizing antibody titers
than seen immediately after primary immunization (a mean
5.3- fold increase). The GMTs and SCRs remained at high lev-
els for 12 months after the booster. A booster dose of IXIARO
was generally well tolerated with a safety proﬁle in line with
the primary immunization.
doi:10.1016/j.ijid.2010.02.615
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Cost effectiveness of Pneumovax® 23 stockpile to prevent
secondary pneumococcal infections among a high-risk
population in the United States during an inﬂuenza pan-
demic
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Background: Recent literature concludes that secondary
bacterial infections (especially pneumococcal infections)
m
o
2
tts e449
ere the leading cause of death during prior inﬂuenza pan-
emics. One strategy to prevent pneumococcal infections
n adults during a future pandemic is to stockpile 23-valent
neumococcal polysaccharide vaccines.
Methods: We developed a model to estimate the health
nd economic impact of a stockpile of Pneumovax® 23
o prevent secondary bacterial infections among high-
isk adults in the age group 18-64 during an inﬂuenza
andemic. We used the model to project the num-
er of pneumococcal cases, hospitalizations, deaths, and
ays of work loss averted. To measure the incremental
ost-effectiveness ratio (ICER), we used the cost per quality-
djusted life year (QALY) metric. We used remaining life
xpectancy of the population following the pandemic as
he analytic horizon. Two pandemic scenarios were exam-
ned to assess differing pandemic severities: 1918 and
958/68. We included the impact of other interventions
lso, such as prepandemic inﬂuenza vaccines, antivirals,
on-pharmacologic interventions, and herd immunity to
neumococcal disease from use of 7-valent pediatric pneu-
ococcal conjugate vaccine (PCV7). Finally, we examined
he impact of Pneumovax® 23 shelf-life, likelihood of a pan-
emic, and stockpile management on the cost-effectiveness
atio.
Results: Under a 1918-type scenario, based on a pop-
lation of 20 million high-risk adults, a Pneumovax® 23
accination program is projected to avoid 185,000 days of
ork loss, 12,100 pneumococcal cases, 1,690 hospitaliza-
ions, and 3,592 deaths. Under a 1958/68 scenario, the
neumovax® 23 vaccination is projected to avert 40,000
ays of work loss, 7,431 pneumococcal cases, 143 hospi-
alizations and 461 deaths. The cost-effectiveness ratios
ICERs) for the Pneumovax® 23 stockpile compared to no
tockpile under the 1918 and 1958/68 scenarios are $4,661
nd $83,039 per QALY respectively. The ICER for Stockpiling
neumovax® 23 increases as the likelihood of a pandemic
ecreases. Given a ﬁxed shelf life of Pneumovax® 23, the
roportion of stockpile that can be put in the mainstream
se every year also affects the ICERs.
Conclusion: Stockpiling Pneumovax® 23 can be a cost-
ffective strategy for reducing the health and economic
urden of pandemic inﬂuenza in the high-risk U.S. popu-
ation.
oi:10.1016/j.ijid.2010.02.616
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ost-effectiveness of the use 23-valent pneumococcal
olysaccharide vaccine to prevent secondary bacterial
nfections related to pandemic inﬂuenza in Brazil
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Background: Secondary bacterial infections contributed
o a signiﬁcant number of deaths during prior inﬂuenza pan-
emics, and have also been shown to be associated with
ortality during the 2009 H1N1 pandemic. The speciﬁc aim
f this analysis was to assess the costeffectiveness of using
3-valent Pneumococcal Polysaccharide Vaccine (PPV23) at
he beginning of or during an inﬂuenza pandemic to prevent
